Vasculitis & polymyalgia rheumatica
Dual myeloperoxidase (MPO)/PR3 anti-neutrophil cytoplasm antibodies (ANCA) positivity and vasculitis: insights from a 7-cases study and an artificial intelligence (AI)-powered literature review
Authors' conclusion
Approximatively 50% of DP-ANCA patients develop AAV, either as drug-induced or idiopathic forms, while the remaining 50%, characterized by pre-existing dysimmune conditions, demonstrates a remarkably low vasculitis risk.
Study context
- Population
- Patients with dual MPO/PR3 ANCA positivity (DP-ANCA): cases from Brest University Hospital immunology laboratory (France), March 2013 to March 2022, and cases from the literatureown cases plus literature cases
- Participants
- 103 patients
- Outcome
- Clinical implications, phenotypic profiles and outcomes of patients with DP-ANCA
Methodological detailsretrospective screening, single-centre case series, AI-based (BIBOT) and manual PubMed literature search
- Retrospective screening
- Single-centre case series
- AI-based (BIBOT) and manual PubMed literature search
Main finding
As reported in the abstract
Phenotypic profiles of DP-ANCA
Idiopathic AAV
∼30%
Drug-induced AAV
∼25%
Autoimmune disease associated with a low risk of developing vasculitis
∼20%
Immune-disrupting comorbidities (infections, cancers, etc) not associated with AAV
∼25%
Observational data: associations, not effects.
Original publication
Dual MPO/PR3 ANCA positivity and vasculitis: insights from a 7-cases study and an AI-powered literature review. Rheumatology (Oxford). Published 29 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →